Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06209606 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT06209606 · ClinicalTrials.gov record · last posted 2024-12-17

Pilot Study Using Changes in Serum BCMA to Determine Disease Progression in Multiple Myeloma

Name: Pilot Study Using Changes in Serum BCMA to Determine Disease Progression in Multiple Myeloma — clinical trial record (NCT06209606)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhaseEarly Phase 1

SponsorOncotherapeutics

Started2022-12-08

View on ClinicalTrials.gov ↗

Record status

This record was last updated December 17, 2024 (before its estimated May 2026 completion). Its status may not reflect the trial's current state.

from the ClinicalTrials.gov record

This is a phase 1, multicenter, open-label study evaluating the safety and efficacy of ruxolitinib, steroids and lenalidomide among MM patients who currently show progressive disease using BCMA to test progression.

Amendment record 2 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 2 times since 2024-01-08; most recent amendment 2024-12-12. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2024-12-12

Status change Not Yet Recruiting→Recruitingv2

Trial Details

NCT Number	NCT06209606
Lead Sponsor	Oncotherapeutics Collaborators: Incyte Corporation
Conditions	Multiple Myeloma
Enrollment	30 participants
Start Date	2022-12-08
Primary Completion	2026-05 (estimated)
Study Completion	2029-02 (estimated)
Updated on ClinicalTrials.gov	2024-12-17